BELLUS Health Announces Positive Top-Line Phase 1 Results For Chronic Cough

On November 19, BELLUS Health announced positive top-line Phase 1 clinical trial results for its chronic cough candidate BLU-5937.

At anticipated therapeutic doses, BLU-5937 did not cause loss of taste perception and has potential to be the best-in-class therapeutic for chronic cough patients who don't respond to current treatments.

The Phase 2 clinical trial for BLU-5937 is expected to begin in mid-2019 with top-line results anticipated in mid-2020.

BLU-5937 may be superior to current leading P2X3 antagonist for chronic cough, Merck's Gefapixant (also named AF-219 and MK-2764), which Merck acquired for US$1.25 billion in 2016.

On November 19, 2018, BELLUS Health Inc. ("BELLUS" or the "Company") (formerly known as Neurochem) (OTCPK:BLUSF) (TSX: BLU.TO) announced positive top-line Phase 1 clinical trial results for its chronic cough drug candidate BLU-5937.

BELLUS is a bio-pharmaceutical development company based in Quebec, Canada. While the Company has other assets, its primary asset is a novel P2X3 antagonist drug, BLU-5937 to treat chronic cough. For more background information about BELLUS, including BLU-5937, please see my August 6, 2018 Seeking Alpha article, "Bellus Health: A Potential Ten Fold Return in the Next 2 Years".

Since August 6th, the share price of BELLUS has increased by more than 60%.

-----------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.